Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix to Market NimbleGen Custom Arrays: Jun 22, 2004 (rev. 1)

NEW YORK, June 22 (GenomeWeb News) -Affymetrix will commercialize NimbleGen's customized microarrays, NimbleGen said today.

 

Under the agreement, Affymetrix will offer its customers made-to-order versions of the NimbleExpress array for use on the Affymetrix GeneChip instrument systems. Customers will be required to place a minimum order of 10 arrays, and there will be a four-week lead time on orders, NimbleGen said.

 

The NimbleExpress array is made using a maskless photolithography, enabling greater flexibility in design than the photolithography masks on traditional Affymetrix arrays.

 

The arrays can interrogate up to 12,000 transcripts for gene expression experiments, and can also be used for genome tiling and other experiments, NimbleGen said.

 

NimbleGen is based in Madison, Wis.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.